# A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

> **NCT07122414** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Forlong Biotechnology Co., Ltd** · enrollment: 80 (estimated)

## Conditions studied

- Non-muscle Invasive Bladder Cancer (NMIBC)

## Interventions

- **DRUG:** FL115
- **DRUG:** FL115+BCG

## Key facts

- **NCT ID:** NCT07122414
- **Lead sponsor:** Suzhou Forlong Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-16
- **Primary completion:** 2027-10-10
- **Final completion:** 2028-10-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07122414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07122414, "A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07122414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*